Ceftaroline for the treatment of prosthetic valve endocarditis due to methicillin-resistant Staphylococcus aureus.

Abstract

The case is described of a frail patient who developed prosthetic valve endocarditis due to methicillin-resistant Staphylococcus aureus (MRSA). Conventional antimicrobial treatments either failed or were contraindicated, and the patient was judged unsuitable for a further valve replacement. A salvage therapy with high doses of a new cephalosporin, ceftaroline, given three times daily was undertaken; subsequently, the patient had not relapsed at two months after completing a six-week course of ceftaroline. Ceftaroline deserves major attention as an alternative choice in difficult-to-treat MRSA endocarditis.

• Authors: Leonardo Pagani, Pierre Bonnin, Cécile Janssen, Emmanuel Desjoyaux, Virginie Vitrat, Jean-Pierre Bru
• Journal: The Journal of heart valve disease (J Heart Valve Dis) Vol. 23 Issue 2 Pg. 219-21 (Mar 2014) ISSN: 0966-8519 [Print] England
• PMID: 25076554 (Publication Type: Case Reports, Journal Article)

Chemical References

• Anti-Bacterial Agents
• Cephalosporins
• T 91825

Topics

• Aged
• Anti-Bacterial Agents (administration & dosage)
• Cephalosporins (administration & dosage)
• Endocarditis, Bacterial (diagnosis, drug therapy, microbiology)
• Frail Elderly
• Heart Valve Prosthesis (adverse effects)
• Heart Valve Prosthesis Implantation (adverse effects, instrumentation)
• Humans
• Male
• Methicillin-Resistant Staphylococcus aureus (isolation & purification)
• Prosthesis-Related Infections (diagnosis, drug therapy, microbiology)
• Staphylococcal Infections (diagnosis, drug therapy, microbiology)
• Treatment Outcome